Evidence map›Paper›PMID 41284376›Full record

ArticleJournal of cellular and molecular medicine2025

Development of a PANoptosis-Related Pathomics Prognostic Model in Ovarian Cancer: A Multi-Omics Study.

Yangyang Zhang, Mengqi Fang, Xuanyu Wang, Zhiwei Ying, Shufan Jiang, Yangyuxiao Lu, Keren He, Shaocong Mo, Fangfang Tao, Ping Lü

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yangyang ZhangShanghai Medical College, Fudan University, Shanghai, China.
Mengqi FangThe First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, China.ORCID 0009-0004-9388-6222
Xuanyu WangCollege of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Zhiwei YingCollege of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Shufan JiangDepartment of Pathology, Shanghai Medical College, Fudan University, Shanghai, China.
Yangyuxiao LuThe First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Keren HeThe First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Shaocong MoDepartment of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Fangfang TaoDepartment of Immunology and Microbiology, Basic Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Ping LüDepartment of TCM, Taizhou First People's Hospital, Hangzhou, Zhejiang, China.

Funding

National Key R&D Program of China 2025YFG0100800National Natural Science Foundation of China 82474460
6 · The paper itself

Abstract

Ovarian cancer (OC) is a high-mortality gynaecological malignancy, and the role of PANoptosis, a comprehensive cell death mechanism, in its prognosis remains unexplored. This study aims to clarify it, potentially guiding OC diagnosis and treatment. We analysed the ovarian data from TCGA and GTEx, and the GSE184880 scRNA-seq dataset from GEO. Spatial data and pathological images were sourced from the 10X Genomics website and GDC Portal. Features were extracted using CellProfiler and ResNet-50, and a PANoptosis-related pathomics prognostic model (PANPM) powered by deep learning was developed. The PANoptosis-related hub gene STAT4 potentially served as a protective factor for patients with OC. A better prognosis in OC was found linked to higher PANoptosis. The PANPM, manifesting distinct advantages for clinical application by accurately extracting pathological features, performed excellently in validation and the high-risk group indicated a poor prognosis. Additionally, STAT4

Indexed as

Biomarkers, TumorGenomicsOvarian NeoplasmsDeep LearningFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMultiomicsPrognosisSTAT4 Transcription FactorBiomarkers, TumorSTAT4 protein, humanSTAT4 Transcription Factormulti‐omics analysisovarian cancerPANoptosispathomics prognostic modelSTAT4

Identifiers

PMID41284376
PMCPMC12643048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.